2022 JGO WORKSHOP

Strategies for Scientific Publication and Literature Analysis

초심자를 위한 논문 읽는 법
(독자입장에서 논문을 읽는 순서, 좋은 논문 여부를 판별하는 법)

이성종

가톨릭의대 서울성모병원 산부인과

Two main tips

- Read actively and read often

- Although there is no one best way to do this........

The structure of research article

| Section	Content
Title	The "take home" message of the entire project, according to the authors.
Abstract	A brief overview of the research question, approach, results, and interpretation. This is the road map or elevator pitch for an article
Introduction	Several paragraphs (or less) to present the research question and why it is important. A newcomer to the field should get a crash course in the field from this section.
Methods	What was done? How was it done? Ideally, one should be able to recreate a project by reading the methods. In reality, the methods are often overly condensed.
Results	What was found? Paragraphs often begin with a statement like this: "To do X, we used approach Y to measure Z." The results should be objective observations.
Figures, tables, & legends,	The data are presented in figures and tables. Legends and captions provide necessary information like abbreviations, summaries of methods, and clarifications.
Discussion	What do the results mean and how do they relate to previous findings in the literature? This is the perspective of the author(s) on the results and their ideas on what might be appropriate next steps. Often it may describe some (often not all!) strengths and limitations of the study: Pay attention to this self-reflection of the author(s) and consider whether you agree or would add to their ideas.

Simple tips

- Pick your reading goal

Classification of different study types

Dtsch Arztebl Int 2009; 106(15): 262–8

Classification of data source

서지 정보원		Full Text	
서지 데이터베이스	인용 데이터베이스	전자저널	Full Text 데이터베이스
PubMed, EMBASE, CINAHL, PsycInfo, KoreaMed 등	Web of Science, Scopus 등	Science Direct, Wiley, Springer, Bentham Science 등	EBSCOhost, ProQuest 등
특정 주제분야	특정 주제분야 전 주제분야	해당 출판사에서 발행하는 저널 Full Text 제공	여러 출판사에서 제공하는 저널 Full Text
서지, 초록 정보	서지, 초록정보 인용정보 제공	Full Text	Full Text
원문 일부 링크	원문 일부 링크	-	Embargo제공

PubMed & MEDLINE & PMC

MEDLINE, PubMed, and PMC (PubMed Central): How are they different?

- PubMed는 3천만 건의 초록정보 및 서지정보를 제공하는 데이터베이스 이다. (MEDLINE과 PMC를 함께 검색하는 Database)

- MEDLINE은 미국 NLM의 주요한 서지 데이터베이스로 생의학, 보건 분야의 2천6백만 건 이상의 서지정보를 포함하고 있다. (5,600여 종 저널이 색인되어 있음)

- PMC는 Full-Text Journal Article 의 전자 아카이브 데이터베이스로, 해당 컨텐츠의 무료 접속(Open Access)을 제공한다. PMC는 6백만 건 이상의 논문을 제공하고 있으며, 대부분은 PubMed에 색인된 논문이 다.

https://www.nlm.nih.gov/bsd/difference.html, https://lib.cuk.ac.kr/bbs/list/14

Mesh: Medical Subject Headings

- **MeSH란 "Medical Subject Headings"의 약어로 미국 국립의학 도서관(NLM)에서 개발한 표준화된 용어로서 계층 구조를 가진 의학용어통제어휘집**

- NLM에서 제작한 통제어휘 시소러스로 약 50년 가량 사용되며 개정된 MEDLINE만의 특징

- 의학용어를 체계적으로 분류하여 각 용어마다 동일한 개념의 각기 다른 용어 및 주제어를 상하위개념(Tree Structure)으로 분석하여 제공

- 현재는 전 세계적으로 표준 화된 의학주제어로 사용하고 있으며, 검색할 때 뿐만 아니라 초록의 주제어(key word)와 의학도서의 분류에도 사용

- MeSH에 사용된 어휘는 30,000개로서 각 MeSH에 특성적 측면을 나타내는 약 80여개의 Subheading(부주제어)이 추가적으로 부여, 세밀한 주제로 검색 가능

- MeSH로 인하여 MEDLINE에 수록된 기사가 효율적으로 색인 / 검색가능

- 엄청난 양의 의학 정보 중에서 원하는 정보를 효과적으로 검색할 수 있게 도와줌

- 저자들마다 다르게 표현되는 동일한 개념을 누락 없이 모두 검색 가능

Evidence Based Medicine

1. Systemic reviews

2. Critically-Appraised Topics(Evidence Syntheses)

3. Critically-Appraised Individual Articles(Article Synopses)

4. RCT(Randomized controlled trials)

5. Cohort studies

6. Case controlled studies, Case series/ reports

7. Background information, Expert Opinion

Six questions

- What do the author(s) want to know (motivation)?

- What did they do (approach/methods)?

- Why was it done that way (context within the field)?

- What do the results show (figures and data tables)?

- How did the author(s) interpret the results (interpretation/discussion)?

- What should be done next? (the key is to ask yourself what you think should come next.)

Steps of Reading

1. Review
2. Reference paper
3. Reference paper
4. Methods and Materials

Steps of Reading

1. Understanding of "Title"
2. Abstract
3. Introduction
4. Results and Conclusion
5. Methods and Materials
6. Reference

1. Table and Figure
2. Reference

figure and table

- Some people like to scrutinize the figures and tables before reading any of the "main text"

- Others prefer to read through the results section while sequentially examining the figures and tables as they are addressed in the text.

- For each figure, work to understand each x- and y-axes, color scheme, statistical approach (if one was used), and why the particular plotting approach was used.

- For each table, identify what experimental groups and variables are presented.

- Identify what is shown and how the data were collected.

How to find good paper

- SCI/SCIE
- Impact factor
- Number of citations
- Authors
- Affiliation
- H-index

https://scholar.google.com/

H-Index

- H-지수는 특정 연구원의 연구 성과를 평가한 지표
- 발표한 논문수와 피인용수를 이용

피인용수 (# of Citation)	논문 수 (No.)
47	1
42	2
32	3
28	4
24	5
22	6
17	7
15	8
10	9
10	10
8	11

https://www.ibric.org/myboard/read.php?Board=news&id=270333

https://scholar.google.com/

[HTML] Efficacy and safety of **pembrolizumab** in previously treated advanced **cervical cancer**: results from the phase II KEYNOTE-158 study.
HC Chung, W Ros, JP Delord, R Perets... - Journal of Clinical ..., 2019 - facultyopinions.com
PURPOSE: KEYNOTE-158 (ClinicalTrials. gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of **pembrolizumab** in multiple **cancer** ...
☆ 저장　🔖 인용　442회 인용　관련 학술자료　전체 9개의 버전　Web of Science: 296　»

https://scholar.google.com/

- Key word
- "Parkinson" vs Parkinson
- Add "review"
- Add "publication year"

+ 첨가, - : 배제

"olaparib" + "ovary cancer" + "bevacizumab" 🔍

검색결과 약 165개 (0.05초)

The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response
M Cámara-Quílez, A Barreiro-Alonso... - Cancers, 2020 - mdpi.com
... Partners MIEN1 and NOP53 in **Ovary Cancer** and Drug ... Individual treatment with paclitaxel or **olaparib** up-regulates NOP53 ... On the other hand, **bevacizumab** diminishes the expression of ...
☆ 저장 ⁇ 인용 5회 인용 관련 학술자료 전체 10개의 버전 Web of Science: 4 ⁇

Olaparib in the treatment of ovarian cancer
CR Washington, DL Richardson, KN Moore - Future Oncology, 2019 - Future Medicine
... 172, 252) [21,22] and addition of **bevacizumab** to CT ... dose escalation study of cediranib and **olaparib**, Safety, dosing and efficacy, 44% response rate in **ovary cancer** patients (another ...
☆ 저장 ⁇ 인용 14회 인용 관련 학술자료 전체 5개의 버전 Web of Science: 10 ⁇

[HTML] **PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports**
T Collot, J Niogret, M Carnet... - Molecular ..., 2021 - spandidos-publications.com
... for a papillary serous **ovary cancer** (diagnosed via ... treatment with carboplatin-gemcitabine-**bevacizumab**; carboplatin allergy ... imaging partial response, **olaparib** maintenance treatment ...
☆ 저장 ⁇ 인용 5회 인용 관련 학술자료 전체 7개의 버전 Web of Science: 4 ⁇

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
CC Gunderson, KN Moore - Future oncology, 2015 - Future Medicine
... second biologic agent for ovarian cancer, following **bevacizumab** ... escalation study of cediranib and **olaparib**, Safety, dosing ... efficacy, 44% response rate in **ovary cancer** patients (another ...
☆ 저장 ⁇ 인용 62회 인용 관련 학술자료 전체 5개의 버전 Web of Science: 39 ⁇

https://scholar.google.com/

Reference & Citation

The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB proteins and their interacting partners MIEN1 and NOP53 in **ovary cancer** and drug-response

M Cámara-Quílez, A Barreiro-Alonso... - Cancers, 2020 - mdpi.com

... Partners MIEN1 and NOP53 in **Ovary Cancer** and Drug ... Individual treatment with paclitaxel or **olaparib** up-regulates NOP53 ... On the other hand, **bevacizumab** diminishes the expression of ...

☆ 저장 ꜙꜙ 인용 5회 인용 관련 학술자료 전체 10개의 버전 Web of Science: 4 ≫

[PDF] mdpi.com
Find it @ CUK Songeui

Olaparib in the treatment of ovarian ca...

CR Washington, DL Richardson, KN Moore - Futur...

... 172, 252) [21,22] and addition of **bevacizumab** ... **olaparib**, Safety, dosing and efficacy, 44% respons...

☆ 저장 ꜙꜙ 인용 14회 인용 관련 학술자료

[HTML] PARP inhibitor resistance and TF... **olaparib** for BRCA-mutated cancer: Fo...

T Collot, J Niogret, M Carnet... - Molecular ..., 202...

... for a papillary serous **ovary cancer** (diagnosed ... **bevacizumab**; carboplatin allergy ... imaging parti...

☆ 저장 ꜙꜙ 인용 5회 인용 관련 학술자료 전...

Olaparib: an oral PARP-1 and PARP-2... cancer

CC Gunderson, KN Moore - Future oncology, 2015...

... second biologic agent for ovarian cancer, follow... and **olaparib**, Safety, dosing ... efficacy, 44% resp...

☆ 저장 ꜙꜙ 인용 62회 인용 관련 학술자료

✕ 인용

MLA Cámara-Quílez, María, et al. "The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response." *Cancers* 12.9 (2020): 2435.

APA Cámara-Quílez, M., Barreiro-Alonso, A., Vizoso-Vázquez, Á., Rodríguez-Belmonte, E., Quindós-Varela, M., Lamas-Maceiras, M., & Cerdán, M. E. (2020). The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response. *Cancers, 12*(9), 2435.

ISO 690 CÁMARA-QUÍLEZ, María, et al. The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB proteins and their interacting partners MIEN1 and NOP53 in ovary cancer and drug-response. *Cancers*, 2020, 12.9: 2435.

BibTeX   EndNote   RefMan   RefWorks

https://scholar.google.com/

"olaparib" + "ovary cancer" "bevacizumab"

학술자료

검색결과 약 165개 (0.03초)

관련도별 정렬
날짜별 정렬

모든 언어
한국어 웹

모든 유형
검토 자료

☐ 특허 포함
☑ 서지정보 포함

✉ 알림 만들기

The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB proteins and their interacting partners MIEN1 and NOP53 in **ovary cancer** and drug-response
M Cámara-Quílez, A Barreiro-Alonso... - Cancers, 2020 - mdpi.com
... Partners MIEN1 and NOP53 in **Ovary Cancer** and Drug ... Individual treatment with paclitaxel or **olaparib** up-regulates NOP53 ... On the other hand, **bevacizumab** diminishes the expression of ...
☆ 저장 〃 인용 5회 인용 관련 학술자료 전체 10개의 버전 Web of Science: 4 ≫

[PDF] mdpi.com
Find it @ CUK Songeui

Olaparib in the treatment of ovarian cancer
CR Washington, DL Richardson, KN Moore - Future Oncology, 2019 - Future Medicine
... 172, 252) [21,22] and addition of **bevacizumab** to CT ... dose escalation study of cediranib and **olaparib**, Safety, dosing and efficacy, 44% response rate in **ovary cancer** patients (another ...
☆ 저장 〃 인용 14회 인용 관련 학술자료 전체 5개의 버전 Web of Science: 10 ≫

[PDF] proquest.com
Find it @ CUK Songeui

[HTML] PARP inhibitor resistance and TP53 mutations in patients treated with **olaparib** for BRCA-mutated cancer: Four case reports
T Collot, J Niogret, M Carnet... - Molecular ..., 2021 - spandidos-publications.com
... for a papillary serous **ovary cancer** (diagnosed via ... treatment with carboplatin-gemcitabine-**bevacizumab**; carboplatin allergy ... imaging partial response, **olaparib** maintenance treatment ...
☆ 저장 〃 인용 5회 인용 관련 학술자료 전체 7개의 버전 Web of Science: 4 ≫

[HTML] spandidos-publications.c...
Find it @ CUK Songeui

https://scholar.google.com/

"olaparib" + "ovary cancer" "bevacizumab"

학술자료

검색결과 약 165개 (0.03초)

The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB proteins and their interacting partners MIEN1 and NOP53 in **ovary cancer** and drug-response

M Cámara-Quílez, A Barreiro-Alonso... - Cancers, 2020 - mdpi.com

... Partners MIEN1 and NOP53 in **Ovary Cancer** and Drug ... Individual treatment with paclitaxel or **olaparib** up-regulates NOP53 ... On the other hand, **bevacizumab** diminishes the expression of ...

☆ 저장 🗩 인용 5회 인용 관련 학술자료 전체 10개의 버전 Web of Science: 4 ≫

[PDF] mdpi.com

Find it @ CUK Songeui

Olaparib in the treatment of ovarian cancer

CR Washington, DL Richardson, KN Moore - Future Oncology, 2019 - Future Medicine

... 172, 252) [21,22] and addition of **bevacizumab** to CT ... dose escalation study of cediranib and **olaparib**, Safety, dosing and efficacy, 44% response rate in **ovary cancer** patients (another ...

☆ 저장 🗩 인용 14회 인용 관련 학술자료 전체 5개의 버전 Web of Science: 10 ≫

[PDF] proquest.com

Find it @ CUK Songeui

[HTML] PARP inhibitor resistance and TP53 mutations in patients treated with **olaparib** for BRCA-mutated cancer: Four case reports

T Collot, J Niogret, M Carnet... - Molecular ..., 2021 - spandidos-publications.com

... for a papillary serous **ovary cancer** (diagnosed via ... treatment with carboplatin-gemcitabine-**bevacizumab**; carboplatin allergy ... imaging partial response, **olaparib** maintenance treatment ...

☆ 저장 🗩 인용 5회 인용 관련 학술자료 전체 7개의 버전 Web of Science: 4 ≫

[HTML] spandidos-publications.c...

Find it @ CUK Songeui

Google 학술검색

알리미

알림 검색어: "olaparib" + "ovary cancer" "bevacizumab"

이메일: sungjonglee25@gmail.com

유형: ⦿ 가장 관련성이 높은 결과   ○ 모든 결과

[결과 업데이트]   [알림 만들기]

2022년 이후의 샘플 결과

"olaparib" + "ovary cancer" "bevacizumab" - 새로운 결과에 대한 검색결과가 없습니다.

Thank you very much kind attention !